1. McGuffin P, Asherson P, Owen M, Farmer A. The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? Br J Psychiatry 1994;164:593–599.
2. Bachmann RF, Schloesser RJ, Gould TD, Manji HK. Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 2005;32:173–202.
3. Bartels SJ, Clark RE, Peacock WJ, Dums AR, Pratt SI. Medicare and medicaid costs for schizophrenia patients byage cohort compared with costs for depression, dementia, and medically ill patients. Am J Geriatr Psychiatry 2003;11:648–657.
4. Bauer M, Un?tzer J, Pincus HA, Lawson WB, NIMH Affective Disorders Workgroup. Bipolar disorder. Ment Health Serv Res 2002;4:225–229.
5. Shih RA, Belmonte PL, Zandi PP. A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. Int Rev Psychiatry 2004;16:260–283.
6. Van Broeckhoven, Verheyen G. Report of the chromosome 18 workshop. Am J Med Genet 1999;88:263–270.
7. Pulver AE, Mulle J, Nestadt G, Swartz KL, Blouin JL, Dombroski B, et al. Genetic heterogeneity in schizophrenia: stratification of genome scan data using co-segregating related phenotypes. Mol Psychiatry 2000;5:650–653.
8. Siris SG. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents. Am J Psychiatry 2000;157:1379–1389.
9. Bailer U, Leisch F, Meszaros K, Lenzinger E, Willinger U, Strobl R, et al. Genome scan for susceptibility loci for schizophrenia and bipolar disorder. Biol Psychiatry 2002;52:40–52.
10. Cardno AG, Rijsdijk FV, Sham PC, Murray RM, McGuffin P. A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry 2002;159:539–545.
11. Potash JB, Zandi PP, Willour VL, Lan TH, Huo Y, Avramopoulos D, et al. Suggestive linkage to chromosomal regions 13q31 and 22q12 in families with psychotic bipolar disorder. Am J Psychiatry 2003;160:680–686.
12. Walss-Bass C, Escamilla MA, Raventos H, Montero AP, Armas R, Dassori A, et al. Evidence of genetic overlap of schizophrenia and bipolar disorder: linkage disequilibrium analysis of chromosome 18 in the Costa Rican population. Am J Med Genet 2005;139:54–60.
13. Escamilla MA. Population isolates: their special value for locating genes for bipolar disorder. Bipolar Disord 2001;3:299–317.
14. Williams NM, Rees MI, Holmans P, Norton N, Cardno AG, Jones LA, et al. A two-stage genome scan for schizophrenia susceptibility genes in 196 affected sibling pairs. Hum Mol Genet 1999;8:1729–1739.
15. Ewald H, Mors O, Koed K, Eiberg H, Kruse TA. Susceptibility loci for bipolar affective disorder on chromosome 18? A review and a study of Danish families. Psychiatr Genet 1997;7:1–12.
16. Maziade M, Roy MA, Rouillard E, Bissonnette L, Fournier JP, Roy A, et al. A search for specific and common susceptibility loci for schizophrenia and bipolar disorder: a linkage study in 13 target chromosomes. Mol Psychiatry 2001;6:684–693.
17. Buyske S. Maternal genotype effects can alias case genotype effects in case-control studies. Eur J Hum Genet 2008;16:784–785.
18. Goddard KA, Tromp G, Romero R, Olson JM, Lu Q, Xu Z, et al. Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered 2007;63:1–16.
19. Schneider K, Knutson F, Tamsen L, Sjöberg O. HLA antigen sharing in preeclampsia. Gynecol Obstet Invest 1997;37:87–90.
20. Wilson ML, Goodwin TM, Pan VL, Ingles SA. Molecular epidemiology of preeclampsia. Obstet Gynecol Surv 2003;58:39–66.
21. Larizza D, Martinetti M, Dugoujon J, Tinelli C, Calcaterra V, Cuccia M, et al. Parental GM and HLA genotypes and reduced birth weight in patients with Turner’s syndrome. J Pediatr Endocrinol Metab 2005;15:1183–1190.
22. Ober C, Simpson JL, Ward M, Radvany RM, Andersen R, Elias S, et al. Prenatal effects of maternal-fetal HLA compatibility. Am J Reprod Immunol Microbiol 1987;15:141–149.
23. Jensen LE, Etheredge AJ, Brown KS, Mitchell LE. Maternal genotype for the monocyte chemoattractant protein 1 A(-2518)G promotor polymorphism is associated with the risk of spina bifida in offspring. Am J Med Genet A 2006;140:1114–1118.
25. Cordell HJ, Barratt BJ, Clayton DG. Case/pseudocontrol analysis in genetic association studies: a unified framework for detection of genotype and haplotype associations, gene-gene and gene-environment interactions and parent-of-origin effects. Genet Epidemiol 2004;26:167–185.
26. Hsieh HJ, Palmer CG, Harney S, Newton JL, Wordsworth P, Brown MA, et al. The v-MFG test: investigating maternal, offspring and maternal-fetal genetic incompatibility effects of disease and viability. Genet Epidemiol 2006;30:333–347.
28. Sinsheimer JS, Palmer CG, Woodward JA. Detecting genotype combinations that increase risk for disease: maternal-fetal genotype incompatibility test. Genet Epidemiol 2003;24:1–13.
33. Chen J, Zheng H, Wilson M. Likelihood ratio tests for maternal and fetal genetic effects on obstetric complications. Genet Epidemiol 2009;33:526–538.
34. Li S, Lu Q, Fu W, Romero R, Cui Y. A regularized regression approach for dissecting genetic conflicts that increase disease risk in pregnancy. Stat Appl Genet Mol Biol 2009;8:45
36. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: The insulin gene region and insulin?dependent diabetes mellitus. Am J Hum Genet 1993;52:506–516.
38. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999;55:997–1004.
39. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, D R. Principal components analysis corrects for stratification in genomewide association studies. Nat Genet 2006;38:904–909.
41. Cordell HJ, Clayton DG. A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. Am J Hum Genet 2002;70:124–141.
42. Schaid DJ. General score tests for associations of genetic markers with disease using cases and their parents. Genet Epidemiol 1996;13:423–449.
43. Schaid DJ, Sommer SS. Genotype relative risks: methods for design and analysis of candidate-gene association studies. Am J Hum Genet 1993;53:1114–1126.
46. Escamilla MA, Spesny M, Reus VI, Gallegos A, Meza L, Molina J, et al. Use of linkage disequilibrium approaches to map genes for bipolar disorder in the Costa Rican population. Am J Med Genet 1996;67:244–253.
47. Mathews CA, Reus VI, Bejarano J, Escamilla MA, Fournier E, Herrera LD, et al. Genetic studies of neuropsychiatric disorders in Costa Rica: a model for the use of isolated populations. Psychiatr Genet 2004;14:13–23.
49. Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatr 1994;51:849–859.
50. Joo EJ, Joo YH, Hong JP, Hwang S, Maeng SJ, Han JH, et al. Korean version of the diagnostic interview for genetic studies: Validity and reliability. Compr Psychiatry 2004;45:225–229.
51. Maxwell ME. Family Interview for Genetic Studies (FIGS): Manual for FIGS. Clinical Neurogenetics Branch, Intramural Research Program. Bethesda, MD: National Institute of Mental Health; 1992.
52. Laird NM, Horvath S, Xu X. Implementing a unified approach to family-based tests of association. Genet Epidemiol 2000;19(Suppl 1):S36–S42.
53. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–265.
55. Ohki I, Shimotake N, Fujita N, Jee J, Ikegami T, Nakao M, et al. Solution structure of the methyl-CpG binding domain of human MBD1 in complex with methylated DNA. Cell 2001;105:487–497.
56. Carney RM, Wolpert CM, Ravan SA, Shahbazian M, Ashley-Koch A, Cuccaro ML, et al. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr Neurol 2003;28:205–211.
57. Greenberg DA, Cayanis E, Strug L, Marathe S, Durner M, Pal DK, et al. Malic enzyme 2 may underlie susceptibility to adolescentonset idiopathic generalized epilepsy. Am J Hum Genet 2005;76:139–146.
58. Itoh S, Itoh F, Goumans M, Dijke P. Signaling of transforming growth factor-β family members through Smad proteins. Eur J Biochem 2000;267:6954–6967.
59. Lu J, Wu Y, Sousa N, Almeida OF. SMAD pathway mediation of BDNF and TGFβ2 regulation of proliferation and differentiation of hippocampal granule neurons. Development 2005;132:3231–3242.
60. Cho MJ, Lee BD, Kim C. Pilot study for family-based association analysis of schizophrenia in a Korean population: Analysis for candidate genes positionally on chromosome 18q21. Asia Pac Psychiatry 2015;7:268–275.
61. Lee BD, Walss-Bass C, Thompson PM, Dassori A, Montero PA, Medina R, et al. Malic enzyme 2 and susceptibility to psychosis and mania. Psychiatry Res 2007;150:1–11.
62. Resh MD. Trafficking and signaling by fatty-acylated and prenylated proteins. Nat Chem Biol 2006;2:584–590.
65. Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and traffic. Nat Rev Mol Cell Biol 2007;8:74–84.
66. Fukata Y, Fukata M. Protein palmitoylation in neuronal development and synaptic plasticity. Nat Rev Neurosci 2010;11:161–175.
67. Schlesinger MJ, Magee AI, Schmidt MF. Fatty acid acylation of proteins in cultured cells. J Biol Chem 1980;255:10021–10024.
68. Fukata M, Fukata Y, Adesnik H, Nicoll RA, Bredt DS. Identification of PSD-95 palmitoylating enzymes. Neuron 2004;44:987–996.
69. Greaves J, Chamberlain LH. DHHC palmitoyl transferases: substrate interactions and (patho) physiology. Trends Biochem Sci 2011;36:245–253.
71. Young FB, Butland SL, Sanders SS, Sutton LM, Hayden MR. Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases. Prog Neurobiol 2012;97:220–238.
72. Yamamoto Y, Chochi Y, Matsuyama H, Eguchi S, Kawauchi S, Furuya T, et al. Gain of 5p15.33 is associated with progression of bladder cancer. Oncology 2007;72:132–138.
73. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM, et al. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet 2008;182:1–11.
75. Oyama T, Miyoshi Y, Koyama K, Nakagawa H, Yamori T, Ito T, et al. Isolation of a novel gene on 8p21.3?22 whose expression is reduced significantly in human colorectal cancers with liver metastasis. Genes Chromosomes Cancer 2000;29:9–15.
76. Birkenkamp-Demtroder K, Christensen LL, Olesen SH, Frederiksen CM, Laiho P, Aaltonen LA, et al. Gene expression in colorectal cancer. Cancer Res 2002;62:4352–4363.
77. Basso AD, Kirschmeier P, Bishop WR. Thematic review series: lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 2006;47:15–31.
78. Yeste-Velasco M, Mao X, Grose R, Kudahetti SC, Lin D, Marzec J, et al. Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol 2014;232:566–577.
79. Greaves J, Chamberlain LH. New links between S-acylation and cancer. J Pathol 2014;233:4–6.
80. Allen KM, Fung SJ, Rothmond DA, Noble PL, Weickert CS. Gonadectomy increases neurogenesis in the male adolescent rhesus macaque hippocampus. Hippocampus 2014;24:225–238.
81. Mortensen PB. The occurrence of cancer in first admitted schizophrenic patients. Schizophr Res 1994;12:185–194.